

VU Research Portal

Pulmonary arterial hypertension in systemic sclerosis

Overbeek, M.J.

2010

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Overbeek, M. J. (2010). *Pulmonary arterial hypertension in systemic sclerosis*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

VII

**Membrane diffusion- and capillary blood volume
measurements are not useful as screening tools
for pulmonary arterial hypertension in systemic sclerosis:
a case-control study**

Maria J.Overbeek*, Herman Groepenhoff, Alexandre E.Voskuyl†, Egbert F. Smit*,
Jochem W.L. Peeters‡, Anton Vonk-Noordegraaf, Marieke D. Spreuwenberg‡,
Ben C. Dijkmans†, Anco Boonstra*

Departments of *Pulmonary Diseases, †Rheumatology, ‡Radiology, †Clinical Epidemiology and
Biostatistics; VU University medical center, The Netherlands.

In: Respiratory Research 2008 1;9:68

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Abstract

Introduction: There is no optimal screening tool for the assessment of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc). A decreasing transfer factor of the lung for CO (TLCO) is associated with the development of PAH in SSc. TLCO can be partitioned into the diffusion of the alveolar capillary membrane (Dm) and the capillary blood volume (Vc). The use of the partitioned diffusion to detect PAH in SSc is not well established yet. This study evaluates whether Dm and Vc could be candidates for further study of the use for screening for PAH in SSc.

Methods: Eleven SSc patients with PAH (SScPAH+), 13 SSc patients without PAH (SScPAH-) and 10 healthy control subjects were included. Pulmonary function testing took place at diagnosis of PAH. TLCO was partitioned according to Roughton and Forster. As pulmonary fibrosis in SSc influences values of the (partitioned) TLCO, these were adjusted for fibrosis score as assessed on HRCT.

Results: TLCO as percentage of predicted (%) was lower in SScPAH+ than in SScPAH- ($41\pm 7\%$ vs. $63\pm 12\%$, $p < 0.0001$, respectively). Dm% in SScPAH+ was decreased as compared with SScPAH- ($22\pm 6\%$ vs. $39\pm 12\%$, $p < 0.0001$, respectively), also after adjustment for total fibrosis score (before adjustment: $B = 17.5$, 95% CI 9.0- 25.9, $p = < 0.0001$; after adjustment: $B = 14.3$, 95% CI 6.0 -21.7, $p = 0.008$). No difference was found in Vc%. There were no correlations between pulmonary hemodynamic parameters and Dm% in the PAH groups.

Conclusion: SScPAH+ patients have lower Dm% than SScPAH- patients. There are no correlations between Dm% and hemodynamic parameters of PAH in SScPAH+. These findings do not support further study of the role of partitioning TLCO in the diagnostic work- up for PAH in SSc.

Introduction

Systemic sclerosis (SSc) is an autoimmune disease characterised by degenerative and fibrotic changes of skin, vasculature and internal organs. Based on the extent of skin thickening, patients are classified in either limited cutaneous SSc (LcSSc) or diffuse cutaneous SSc (DcSSc)[1]. In general, patients with LcSSc are at higher risk of pulmonary arterial hypertension (PAH), which is the leading cause of death in this group of patients[2,3]. SScPAH patients have a poor prognosis with a 3-year survival rate of 50% despite therapy [4,5]. As therapeutic intervention implemented at an earlier phase might modify the disease course in SScPAH, new tools that assess PAH in patients with SSc are warranted[6].

In this study we evaluate whether the components of the transfer factor of the lung for carbonmonoxide (TLCO), the conductance of the alveolar capillary membrane (Dm) and the pulmonary capillary blood volume (Vc) as assessed by the Roughton-Forster method [7], could be candidates for further studies in the search for tools for the diagnostic work-up for PAH in SSc patients. The TLCO is reduced in patients with pulmonary arterial hypertension (PAH) to generally 65%-72% of predicted [8-12]. In patients with LcSSc, TLCO is reduced to an average of 40% of predicted at the time of diagnosing PAH, and TLCO values of less than 50% of predicted have been detected in patients with LcSSc without interstitial fibrosis 4.5 years before PAH was diagnosed[2,13]. However, TLCO has not been established yet as a marker for SScPAH. It remains to be elucidated how interstitial lung disease influences TLCO in these patients as severe interstitial lung disease (defined by VC <70%) was excluded from these studies, although a decrease in TLCO in combined restrictive lung disease and pulmonary hypertension in SSc as compared with isolated pulmonary hypertension in SSc has been suggested [14]. Moreover, Mukerjee *et al.* demonstrated only a weak correlation between mPpa and TLCO in SSc patients [15]. The components of the partitioned TLCO, however, might demonstrate (proportional) changes in SSc patients with PAH as compared with SSc patients without PAH. As patterns of Dm and Vc have not been evaluated in these patient groups before, we compared TLCO, Dm and Vc between SSc patients with PAH (SScPAH+) and SSc patients without PAH (SScPAH-). We also investigated the relation between the two components of TLCO and PAH, by calculating correlations between Dm and Vc and haemodynamic parameters obtained during right heart catheterisation.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Methods

Patient population

Systemic sclerosis patients with PAH (SScPAH +) and without PAH (SScPAH-) attending the outpatient clinic of the VU University medical center between February 2004 and December 2006 were identified. Patient charts were reviewed from February 2004 onward, as since that date partitioned membrane diffusion measurements were consistently implemented according to the method described below.

In the SScPAH+ group, patients were included if they had undergone pulmonary function testing according to the method described below and an HRCT scan one day before diagnosis of PAH. PAH was diagnosed at a mean pulmonary artery pressure (mPpa) of ≥ 25 mmHg, a pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg, and a pulmonary vascular resistance of > 240 dynes \times s \times cm⁻⁵ measured by right heart catheterisation.

In the SScPAH- group, PAH was excluded by means of right heart catheterisation or a systolic Ppa < 30 mmHg estimated from the tricuspid regurgitation jet[15]. Patients were excluded if they had clinical or echocardiographic signs of left ventricular heart disease. Pulmonary function testing in this group had to be performed within 1 day of right heart catheterisation or echocardiography. A time lapse of 6 months between pulmonary function testing and HRCT scan was accepted. SSc was classified according to the LeRoy classification system[1]. Ten healthy, non-smoking persons underwent pulmonary function testing to form a control group for TLCO, Dm and Vc measurements.

Pulmonary function

Static and dynamic lung volumes

Forced expiratory flow in 1 s (FEV1), forced vital capacity (FVC), vital capacity (VC) and total lung capacity (TLC) were assessed with standard pulmonary function test equipment (\dot{V} max 22 and 6200, Sensor Medics, Yorba Linda, CA, U.S.A.). Measurements were performed according to ERS guidelines[16].

TLCO measurement

TLCO was measured by single-breath method breathing room air of 21% O₂ and a gas mixture of 0.3% carbon monoxide (CO), 0.3% methane (CH₄), 21% oxygen (O₂) balanced with nitrogen (N₂) starting at residual volume to TLC followed by a ten seconds breath hold meeting ERS guidelines [16].

Determination of Dm and Vc

Dm and Vc and were measured at different alveolar oxygen concentrations. All measurements were performed in duplicate. The linearity of the relation using four different oxygen concentrations (21%, 40%, 60% and 80%) under our experimental conditions was verified in a group of 8 healthy controls and 10 patients with pulmonary arterial hypertension. Moreover, the sensitivity of Vc measurement was verified by means of assessment of Vc in erect and supine position according to [17](data not shown). The first manoeuvre was performed as described above, after breathing room air. The second manoeuvre took place after breathing 60% O₂ for five minutes, immediately followed by the single breath measurement with a gas mixture of 0.3% carbon monoxide (CO), 0.3% methane (CH₄), 60 % oxygen (O₂) balanced with nitrogen (N₂).

Dm and Vc were calculated according to the Roughton-Forster equation:

$$1/\text{TLCO} = 1/\text{DmCO} + 1/\theta\text{CO} * \text{Vc} [7]$$

where θCO is the rate of reaction of CO with hemoglobin (Hb) and $1/\theta$ is the specific transfer resistance from the red cell membrane to the haemoglobin molecule.

θ is determined by the following equation: $(\alpha + \beta * \text{PAO}_2) * [\text{Hbst} / \text{Hb}]$, where $\alpha = 0.001$ and $\beta = 0.000134$ and $[\text{Hbst}/\text{Hb}]$ is a standardised normal Hb value divided by the haemoglobin concentration of the patient [18]. For PAO_2 a value of 13.21 mmHg was used, derived from the alveolar gas equation[19].

By the mean of the two values of TLCO measured at each alveolar O₂ concentration and θ , a plot of $1/\text{TLCO}$ against $1/\theta$ is obtained. $1/\text{Dm}$ is given by the y-intercept and $1/\text{Vc}$ is given by the slope of the straight line.

We utilised reference equations as described by Zanen *et al.*[20], as they applied a technique that is similar to ours and because their equations have lower standard deviations (while showing similar relationships between height, age and $1/\text{Vc}$ and $1/\text{DmCO}$) than previous studies. After calculating the 95% confidence interval (CI), measured values obtained in normal subjects in our laboratory are within the normal range (data not shown). The reproducibility of the technique is regularly assessed in our laboratory.

Dm and Vc values outside the 95% CI, calculated with the reference equations using parameters height, age and gender, and the reference equation's standard deviations, were considered abnormal. For the evaluation of the proportionality of change of Dm in respect to Vc, the $\text{Dm}\%/\text{Vc}\%$ ratio, with both values presented as percentages of predicted, was calculated. A disproportionate reduction of Dm relative to Vc is indicated by a ratio less than 1[21].

R1
R2
R3
R4
R5
R6
R7
R8
R9
R1
R1
R1
R1
R1
R1
R1
R1
R1
R1
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3

Analysis of hemodynamic parameters

Pulmonary capillary wedge pressure (PCWP) was measured in order to exclude left sided heart disease and calculate pulmonary vascular resistance (PVR). Cardiac output (CO) was calculated by the Fick method and PVR was calculated by $(mPpa - PCWP) / CO$.

HRCT

As interstitial fibrosis is a known feature in LcSSc [22], affecting Dm and Vc, interstitial fibrosis was evaluated by means of HRCT. HRCT had to be performed within 6 months of lung function testing. All HRCTs consisted of 1.0 mm thick sections taken at 1 cm intervals throughout the entire thorax (CT Sensation 64; Siemens; Erlangen; Germany). No intravenous contrast was administered. Three independent readers scored reticular opacity and ground glass on a scale of 0-5 for each lobe, with a maximum of 50, according to the scoring system described by Kazerooni *et al.* [23]. These scores were also added and are reported as the total fibrosis score [24].

Statistical analysis

SPSS 12.0 software package (Chicago, IL) was used for statistical analyses, and $p < 0.05$ was considered statistically significant. Normal distribution was evaluated by Shapiro-Wilkinson's test. One-way analysis of variance was performed for comparisons between groups. Because of multiple testing the threshold for significance was adjusted using the Bonferroni correction for families of tests. Student t test was used for comparison of HRCT fibrosis scores and haemodynamics parameters between the SScPAH+ group and (the catheterised patients from) the SScPAH- group. Values in tables are expressed as mean \pm SD, and in figures as mean \pm SE.

Results

Patient population

Twenty-four patients were included, 11 SScPAH+ patients and 13 SScPAH- patients. Patient characteristics are shown in Table 1. The mean age of the SScPAH+ patients differed significantly neither from the SScPAH- patients nor from the control subjects. All SSc patients suffered from the limited cutaneous form of the disease. Height and gender were similar in the groups. SScPAH+ patients and SScPAH- were similar with respect to SSc classification and modified Rodnan skin score. Duration of Raynaud symptoms at diagnosis of SSc was significantly longer in the SScPAH+ group than in the SScPAH- group ($p = 0.009$).

Six out of 13 patients of the SScPAH- group had undergone right heart catheterisation. The SScPAH + patients had significantly lower SvO₂ as compared with the group of 6 catheterised SScPAH- patients. All patients had a SaO₂ of > 92% and higher. The total score of fibrosis and ground glass did not differ between the SScPAH+ and SScPAH- group.

Table 1. Demographic data

	SScPAH+ N=11	SScPAH- N=13	Control N=10
Age, yrs	70 ± 10	66 ± 11	60 ± 7
Height, m	1.6 ± 0.1	1.7 ± 0.1	1.7 ± 0.1
Male/Female	0/9	0/12	2/8
Limited cutaneous SSc (%)	100	100	
Haemoglobin, mmol/l	7.8 ± 1.2	8.0 ± 0.6	8.6 ± 0.8
Raynaud's phenomenon (%)	100	92	
Raynaud's phenomenon at PFT, yrs	19 ± 11*	7 ± 8	
Autoantibodies (n)			
ANA	10	12	
Anti-centromere	7	6	
Anti-topoisomerase	0	5	
Modified Rodnan skin score	14.1 ± 5.7	11.9 ± 5.9	
Smoking status			
Never/former/current (no.)	7/3/1	6/4/2	8/2/0
6-minute walking distance, m	326 ± 102	430 ± 127	
SvO ₂ , %	63 ± 7*	73 ± 2	
HRCT fibrosis score [†]	4.9 ± 3.4	4.1 ± 3.4	
HRCT ground glass score	7.1 ± 5.8	3.1 ± 5.5	
HRCT total fibrosis score [‡]	12.1 ± 6.8	7.4 ± 8.5	

Values expressed as mean ±SD, otherwise as stated. Abbreviations: SScPAH+: systemic sclerosis associated pulmonary arterial hypertension. SScPAH-: SSc without PAH. PFT: pulmonary function testing. ANA: anti-nucleolar antibodies. SvO₂: mixed venous oxygen saturation. * p < 0.05 for comparison of SScPAH+ with SScPAH-. [†] According to reference 23. [‡] According to reference 24.

Pulmonary function testing

Results of pulmonary function testing are outlined in Table 2. No signs of either obstructive or restrictive airway disease were found in the patient groups (Table 2). TLCO was impaired in both patient groups as compared with controls. SScPAH+ patients had significantly lower TLCO% values than SScPAH- (p < 0.0001) (Figure 1A). All SScPAH+ and SScPAH- patients had reduced Dm%. Dm% values in SScPAH+ patients were significantly lower than in the SScPAH- group (Figure 1B), also after adjustment for total fibrosis score (before adjustment: B = 17.5, 95% CI 9.0- 25.9, p = < 0.0001; after adjustment: B = 14.3, 95% CI 6.0 -21.7, p= 0.008). Figure

R1
R2
R3
R4
R5
R6
R7
R8
R9
R1
R1
R1
R1
R1
R1
R1
R1
R1
R1
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3

1 demonstrates overlap of Dm% values between the SScPAH+ and SScPAH- groups, a finding also observable for TLCO%.

Vc % was significantly decreased in the patient groups as compared with the control group, however, between the patient groups there was no significant difference. The Vc%/Dm% ratio was significantly higher in SScPAH+ as compared with SScPAH- and controls (p = 0.01 and p < 0.0001). These values also demonstrated overlap between the groups (Figure 2).

Table 2. Static and dynamic lung volumes

	SScPAH+ N=11	SScPAH- N=13	Control N= 10
FVC, % pred	98 ± 21 [†]	103 ± 22	122 ± 17
FEV1, % pred	84 ± 12 [†]	93 ± 20	108 ± 12
FEV1/VC	69 ± 10	73 ± 7	74 ± 6
TLC, % pred	90 ± 17	91 ± 14	
TLCO, % pred	41 ± 7 ^{**}	63 ± 12 [‡]	93 ± 15
Dm, mmol·min ⁻¹ ·kPA ⁻¹	4 ± 1 ^{**}	7.5 ± 2.8 [‡]	15 ± 4
Dm,% pred	21.7 ± 5.8 ^{**}	39.2 ± 12.4 [‡]	81 ± 18
Vc, ml	40 ± 14	46 ± 14	56 ± 16
Vc, % pred	60 ± 25 [†]	62 ± 18 [‡]	83 ± 11
Dm%/Vc %	0.41 ± 0.25 [†]	0.71 ± 0.37	1.00 ± 0.26
Vc%/Dm %	3.0 ± 1.5 ^{**}	1.7 ± 0.7	1.06 ± 0.26

Values expressed as mean ±SD. Abbreviations: SScPAH+: systemic sclerosis-associated pulmonary arterial hypertension; SScPAH-: SSc without PAH. FEV1 %: forced expiratory volume, percentage of predicted. TLC: total lung capacity. TLCO: transfer factor of the lung for carbon monoxide. Dm: diffusing capacity of the alveolar capillary membrane.

Vc: pulmonary capillary volume. * p < 0.05 for comparison of SScPAH+ with SScPAH-;

† p < 0.05 for comparison of SScPAH+ with control. ‡ p < 0.05 for comparison of SScPAH- with control

Relationship between pulmonary and cardiovascular function

Haemodynamic data resulting from right heart catheterisation are shown in table 3. No significant correlations between TLCO%, Dm%, Vc% and mPpa, PVR, SvO2 and PAH- prognostic parameters such as CI and mean right atrial pressure [10], were found, nor for the Dm%/Vc% or Vc%/Dm% ratios and those hemodynamic parameters. The relation between Vc%/Dm% and PVR and mPpa is illustrated in figure 3.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Table 3. Haemodynamic parameters

	SScPAH+ N=11	SScPAH- N=6
mPra, mmHg	4.5 ± 1.8	2.8 ± 2.2
mPpa, mmHg	36.7 ± 5.7*	18.0 ± 2.4
PVR, dynes/s·m ⁵	625 ± 218*	117 ± 28
PCWP, mmHg	8.7 ± 4.0	7.8 ± 3.8
CI, l/m ²	2.3 ± 0.3*	3.4 ± 0.9

Values expressed as mean ±SD. Definition of abbreviations: SScPAH+: systemic sclerosis-associated pulmonary arterial hypertension; SScPAH-: SSc without PAH. mPra: mean right atrial pressure; Ppa: pulmonary artery pressure; PVR: pulmonary vascular resistance; CI: cardiac index; PCWP: pulmonary capillary wedge pressure.* p < 0.05 for comparison of SScPAH+ with SScPAH-




Figure 3

The relation between the ratio of the pulmonary capillary blood volume as percentage of predicted and the diffusion capacity of the alveolar capillary membrane as percentage of predicted ($V_c\%/D_m\%$) and the pulmonary vascular resistance (PVR) and the mean pulmonary artery pressure (mPpa) in patients with systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) ($r^2 = 0.16$, $p = 0.23$ and $r^2 = 0.07$, $p = 0.52$, respectively).

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Despite these suggestions, it is difficult to completely explain the underlying mechanisms of our findings. The Roughton-Forster equation assumes that $1/\text{TLCO}$ is the sum of two resistances representing either alveolocapillary wall disease (D_m) or abnormalities on the vascular level (V_c). However, D_m and V_c may not act as independent entities. Decrease in capillary flow, affecting V_c , results in reduction in surface area in affected tissue and therefore in a decrease of D_m [25]. Moreover, this decrease in D_m due to decrease in V_c could be disproportional as is shown by a mathematical model[21]. Irregular perfusion in pulmonary vascular disease [36,37], which is a result of the distension of remaining vasculature in reaction to curtailment of pulmonary vessels in PAH and/or fibrosis, may also result in unpredictable behaviour of D_m and V_c .

Correlation between hemodynamic parameters of PAH and D_m and V_c values

No relations between hemodynamic parameters of pulmonary hypertension and D_m or V_c were found. Correlations between hemodynamic values and the two components of TLCO have been reported scarcely. Steenhuis *et al.* found an association between absolute D_m and PVR in patients with IPAH ($r=0.54$, $p = 0.04$), which disappeared when using the predicted value of D_m [11]. Others showed an inverse relationship between $mPpa$ and V_c in a group with miscellaneous forms of PAH, whereas they did not find the correlation between D_m and $mPpa$ [21]. Bonay *et al.* showed a relationship between V_c/D_m ratio and systolic Ppa values in patients with chronic infiltrative lung disease[27]. Although in our study these values differed significantly between the groups, no such a relationship was found. We also performed measurements of D_m and V_c in a group of 14 patients with idiopathic PAH (IPAH); we did not find any relation between D_m , V_c , or their ratios and hemodynamic parameters in this PAH population either (data not shown). Taken together, these findings limit the clinical value of partitioning TLCO in SSc and SScPAH.

A limitation of this study is the small patient number. Methodological limitations include the acquisition of the D_m component that might be prone to inaccuracy: a small change of the slope of the $1/\text{TLCO}-1/\theta$ line can lead to a large change at the y-intercept that determines D_m . However, we believe that this leads to a systematic error without consequences for the proportionality of the values between the patient groups. We used two different oxygen concentrations for the determination of TLCO as has been used by others as well [11,20,21,27,31,38,39]; the linearity of the slope was verified in our experimental conditions using four oxygen concentrations. Moreover, to maximize preciseness, we performed duplicate measurements. One SScPAH+ and two SScPAH- patients were current smokers, although not heavily

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Reference List

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., Rowell N, Wollheim F: **Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.** *J Rheumatol* 1988, **15**: 202-205.
2. Steen V, Medsger TA, Jr.: **Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.** *Arthritis Rheum* 2003, **48**: 516-522.
3. Steen VD, Medsger TA: **Changes in causes of death in systemic sclerosis, 1972-2002.** *Ann Rheum Dis* 2007, **66**: 940-944.
4. Fisher MR, Mathai SC, Champion HC, Girgis RE, Houston-Harris T, Hummers L, Krishnan LA, Wigley F, Hassoun PM.: **Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.** *Arthritis Rheum* 2006, **54**: 3043-3050.
5. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE: **Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.** *Chest* 2003, **123**: 344-350.
6. Galie N, Rubin LJ, Hoeper MM, Jansa P, Kusic-Pajic, Simmoneau G. **Bosentan improves hemodynamics and delays time to clinical worsening in patients with mildly symptomatic Pulmonary Arterial Hypertension (PAH): results of the EARLY study.** *European Heart Journal* **28**, 140. 2007.
Ref Type: Abstract
7. Roughton FJ., FORSTER RE: **Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries.** *J Appl Physiol* 1957, **11**: 290-302.
8. Sun XG, Hansen JE, Oudiz RJ, Wasserman K: **Pulmonary function in primary pulmonary hypertension.** *J Am Coll Cardiol* 2003, **41**: 1028-1035.
9. Burke CM, Glanville AR, Morris AJ, Rubin D, Harvey JA, Theodore J, Robin ED. **Pulmonary function in advanced pulmonary hypertension.** *Thorax* 1987, **42**: 131-135.
10. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. **Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.** *Ann Intern Med* 1991, **115**: 343-349.
11. Steenhuis LH, Groen HJ, Koeter GH, van der Mark TW: **Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension.** *Eur Respir J* 2000, **16**: 276-281.
12. van dL, I, Zanen P, Grutters JC, Snijder RJ, van den Bosch JM: **Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.** *Chest* 2006, **129**: 378-383.

13. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA, Jr.: **Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.** *Arthritis Rheum* 1986, **29**: 515-524.
14. Chang B, Wigley FM, White B, Wise RA: **Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.** *J Rheumatol* 2003, **30**: 2398-2405.
15. Mukerjee D, St George D, Knight C, Davar J, Wells AU, du Bois RM, Black CM, Coghlan JG. **Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis.** *Rheumatology (Oxford)* 2004, **43**: 461-466.
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: **Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.** *Eur Respir J Suppl* 1993, **16**: 5-40.
17. Chang SC, Chang HI, Liu SY, Shiao GM, Perng RP: **Effects of body position and age on membrane diffusing capacity and pulmonary capillary blood volume.** *Chest* 1992, **102**: 139-142.
18. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC: **Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.** *Eur Respir J Suppl* 1993, **16**: 41-52.
19. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ: *Principles of exercise testing and interpretation; including pathophysiology and clinical interpretation*, 3 edn. Baltimore: 1999.
20. Zanen P, van der LL, van der MT, van den Bosch JM: **Reference values for alveolar membrane diffusion capacity and pulmonary capillary blood volume.** *Eur Respir J* 2001, **18**: 764-769.
21. Oppenheimer BW, Berger KI, Hadjiangelis NP, Norman RG, Rapoport DM, Goldring RM: **Membrane diffusion in diseases of the pulmonary vasculature.** *Respir Med* 2006, **100**: 1247-1253.
22. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connolly K, Metersky M, Furst DE: **Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.** *Ann Rheum Dis* 2007.
23. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, White RI, Lynch JP, Toews G: **Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring.** *AJR Am J Roentgenol* 1997, **169**: 977-983.
24. Gay SE, Kazerooni EA, Toews GB, Lynch JP, III, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, White RI, Popovitch J, Hyzy R, Martinez FJ: **Idiopathic pulmonary fibrosis: predicting response to therapy and survival.** *Am J Respir Crit Care Med* 1998, **157**: 1063-1072.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R1
R1
R1
R1
R1
R1
R1
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

25. Pande JN, Gupta SP, Guleria JS: **Clinical significance of the measurement of membrane diffusing capacity and pulmonary capillary blood volume.** *Respiration* 1975, **32**: 317-324.
26. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R: **Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis.** *Am Rev Respir Dis* 1991, **143**: 219-225.
27. Bonay M, Bancal C, de Zuttere D, Arnoult F, Saumon G, Camus F: **Normal pulmonary capillary blood volume in patients with chronic infiltrative lung disease and high pulmonary artery pressure.** *Chest* 2004, **126**: 1460-1466.
28. Diot E, Boissinot E, Asquier E, Guilmot JL, Lemarie E, Valat C, Diot P: **Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis.** *Chest* 1998, **114**: 1623-1629.
29. Hsia CC, Chuong CJ, Johnson RL, Jr.: **Red cell distortion and conceptual basis of diffusing capacity estimates: finite element analysis.** *J Appl Physiol* 1997, **83**: 1397-1404.
30. Spengler MI, Svetaz MJ, Leroux MB, Leiva ML, Bottai HM: **Association between capillaroscopy, haemorheological variables and plasma proteins in patients bearing Raynaud's phenomenon.** *Clin Hemorheol Microcirc* 2004, **30**: 17-24.
31. Crapo RO, Morris AH, Gardner RM: **Reference values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume.** *Bull Eur Physiopathol Respir* 1982, **18**: 893-899.
32. Georges R, Saumon G, Loiseau A: **The relationship of age to pulmonary membrane conductance and capillary blood volume1.** *Am Rev Respir Dis* 1978, **117**: 1069-1078.
33. Huez S, Roufousse F, Vachiere JL, Pavelescu A, Derumeaux G, Wautrecht JC, Cogan E, Naeije R: **Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?** *Eur Respir J* 2007, **30**: 928-936.
34. Abraham D, Distler O: **How does endothelial cell injury start? The role of endothelin in systemic sclerosis.** *Arthritis Res Ther* 2007, **9 Suppl 2**: S2.
35. Varga J, Abraham D: **Systemic sclerosis: a prototypic multisystem fibrotic disorder.** *J Clin Invest* 2007, **117**: 557-567.
36. Hansell DM: **Small-vessel diseases of the lung: CT-pathologic correlates.** *Radiology* 2002, **225**: 639-653.
37. Wilson AG, Harris CN, Lavender JP, Oakley CM: **Perfusion lung scanning in obliterative pulmonary hypertension.** *Br Heart J* 1973, **35**: 917-930.
38. Bernstein RJ, Ford RL, Clausen JL, Moser KM: **Membrane diffusion and capillary blood volume in chronic thromboembolic pulmonary hypertension.** *Chest* 1996, **110**: 1430-1436.
39. Lamberto C, Nunes H, Le Toumelin P, Duperron F, Valeyre D, Clerici C: **Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange.** *Chest* 2004, **125**: 2061-2068.
40. Steen VD, Lucas M, Fertig N, Medsger TA, Jr.: **Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.** *J Rheumatol* 2007, **34**: 2230-2235.